These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26987067)

  • 1. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
    Banerjee Y; Santos RD; Al-Rasadi K; Rizzo M
    Atherosclerosis; 2016 May; 248():62-75. PubMed ID: 26987067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 and cancer: Rethinking the link.
    Mahboobnia K; Pirro M; Marini E; Grignani F; Bezsonov EE; Jamialahmadi T; Sahebkar A
    Biomed Pharmacother; 2021 Aug; 140():111758. PubMed ID: 34058443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypercholesterolemia: The role of PCSK9.
    Melendez QM; Krishnaji ST; Wooten CJ; Lopez D
    Arch Biochem Biophys; 2017 Jul; 625-626():39-53. PubMed ID: 28587771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of PCSK9 inhibition and its effects beyond LDL receptors.
    Dixon DL; Trankle C; Buckley L; Parod E; Carbone S; Van Tassell BW; Abbate A
    J Clin Lipidol; 2016; 10(5):1073-80. PubMed ID: 27678423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PCSK9 inhibitors : New treatment option in clinical practice].
    Müller-Wieland D; Marx N
    Herz; 2016 Jun; 41(4):290-5. PubMed ID: 27215418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
    Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
    Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
    Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 and Hypercholesterolemia: Therapeutic Approach.
    Obradovic M; Zaric B; Sudar-Milovanovic E; Ilincic B; Stokic E; Perovic M; Isenovic ER
    Curr Drug Targets; 2018; 19(9):1058-1067. PubMed ID: 29210646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
    Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives.
    Tsouka AN; Tellis CC; Tselepis AD
    Curr Pharm Des; 2018; 24(31):3622-3633. PubMed ID: 30317986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9.
    Alkindi M; Siminovitch KA; Gupta M; Genest J
    Can J Cardiol; 2016 Dec; 32(12):1552-1560. PubMed ID: 27523271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
    Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
    Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
    Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
    Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.